Cargando…

PB1941: PRELIMINARY EXPLORATION OF PROLONGED USE OF ELTROMBOPAG IN PATIENTS WITH NAÏVE SEVERE APLASTIC ANEMIA IN THE REAL WORLD: DURATION AND EFFICACY

Detalles Bibliográficos
Autores principales:	Li, R., Liu, Z., Chen, X., Long, Q., Yang, Y., Lin, S., Jia, J., He, G., Li, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431749/ http://dx.doi.org/10.1097/01.HS9.0000850604.52031.e8

Ejemplares similares

PB2069: ELTROMBOPAG WITH IMMUNO SUPPRESSIVE THERAPY IN SEVERE ACQUIRED APLASTIC ANEMIA IN CHILDREN AND ADOLESCENTS: A MONOCENTRIC EXPERIENCE
por: Sayed, Nesrine Ben, et al.
Publicado: (2023)

PB2041: COMPARISON OF ELTROMBOPAG AND AVATROMBOPAG IN THE TREATMENT OF REFRACTORY/RELAPSED APLASTIC ANEMIA, A SINGLE CENTER STUDY IN CHINA
por: Zhang, Zhuxin, et al.
Publicado: (2023)

PB1949: ELTROMBOPAG IN CHINESE PATIENTS WITH REFRACTORY OR RELAPSED SEVERE APLASTIC ANEMIA: A NON-RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF ELTROMBOPAG
por: Chang, H., et al.
Publicado: (2022)

PB2479: ELTROMBOPAG, BUT NOT AVATROMBOPAG, REGULATES BONE MARROW MICROENVIRONMENT MIMICKING APLASTIC ANEMIA THROUGH DOWN-REGULATION OF FERROPTOSIS INHIBITOR
por: Ji, Jiang, et al.
Publicado: (2023)

PB1941: MIND-BODY INTERVENTION PROLONGS LYMPHOCYTE DOUBLING TIME AND TREATMENT-FREE SURVIVAL IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Shapira, Shirley, et al.
Publicado: (2023)

PB2055: PREGNANCY IN PATIENTS WITH APLASTIC ANEMIA – CLINICAL OBSERVATIONS
por: Shilova, Elene, et al.
Publicado: (2023)

Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
por: Konishi, Akiko, et al.
Publicado: (2019)

PB2037: NEW TERT VARIANT IN A FAMILY WITH APLASTIC ANEMIA
por: Virijevic, Marijana, et al.
Publicado: (2023)

PB1950: MASS CYTOMETRY ANALYSIS IDENTIFIES T CELL IMMUNE SIGNATURE FOR APLASTIC ANEMIA AND PREDICTS RESPONSE TO CYCLOSPORINE
por: Zhang, L., et al.
Publicado: (2022)

PB2066: SYSTEMIC LUPUS ERYTHEMATOSUS-INDUCED AMEGAKARYOCYTIC THROMBOCYTOPENIA AND SUBSEQUENT APLASTIC ANEMIA
por: Seong, Gyuhee, et al.
Publicado: (2023)

PB1932: GENERIC ELTHROMBOPAG WITH STANDARD IMMUNOSUPPRESSIVE THERAPY IN SEVERE APLASTIC ANEMIA
por: Ranjit Kumar, C., et al.
Publicado: (2022)

Eltrombopag for the treatment of aplastic anemia: current perspectives
por: Lum, Su Han, et al.
Publicado: (2016)

Aplastic Anemia Treated with Eltrombopag during Pregnancy
por: Suminaga, Yuri, et al.
Publicado: (2022)

PB1935: MANAGEMENT OF NON-SEVERE APLASTIC ANEMIA: LABORATORY WORKUP AND TREATMENT PATTERNS.
por: Cassanello, G., et al.
Publicado: (2022)

PB1940: ACQUIRED APLASTIC ANEMIA: THE CHALLENGE OF TREATMENT IN MEXICO. SINGLE HEMATOLOGY CENTER EXPERIENCE
por: Guajardo Leal, M. L., et al.
Publicado: (2022)

Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia
por: Zhao, Yufei, et al.
Publicado: (2023)

PB2311: LOW-DOSE PREDNISON AND ELTROMBOPAG COMBINATION AS FRONTLINE TREATMENT IN NEWLY DIAGNOSED ITP PATIENTS
por: Liu, S.-Y., et al.
Publicado: (2022)

PB2046: CHANGINGS IN GENETIC DEFINITION AND MANAGEMENT OF ACQUIRED APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE
por: Bortolotti, Marta, et al.
Publicado: (2023)

Current evidence and the emerging role of eltrombopag in severe aplastic anemia
por: Drexler, Beatrice, et al.
Publicado: (2021)

Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag
por: Zaimoku, Yoshitaka, et al.
Publicado: (2021)

PB2038: THE POTENTIAL MECHANISM OF TCM TREATMENT OF CHRONIC APLASTIC ANEMIA BASED ON DATA MINING AND NETWORK PHARMACOLOGY
por: Si, Yuping, et al.
Publicado: (2023)

PB2048: HEMATOLOGIC RECOVERY INDUCED BY AVATROMBOPAG IN SAA REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG
por: Liu, Xiaoqing, et al.
Publicado: (2023)

PB2049: THE EFFICACY OF HETROMBOPAG PLUS CYCLOSPORINE A IN PATIENTS WITH TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA: A PROSPECTIVE REGISTRY STUDY
por: Gong, Yuemin, et al.
Publicado: (2023)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
por: Chang, Hong, et al.
Publicado: (2023)

Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan
por: Imada, Kazunori, et al.
Publicado: (2020)

PB2550: EXPLORATION OF B-CELL RECEPTOR AND T-CELL RECEPTOR REPERTOIRES REVEALS DISTINCT MECHANISMS IN PURE RED CELL APLASIA, AUTOIMMUNE HEMOLYTIC ANEMIA AND APLASTIC ANEMIA
por: Zhang, Ruoxi, et al.
Publicado: (2023)

PB2466: PERIPHERAL BLOOD AS GRAFT SOURCE FOR APLASTIC ANEMIA TRANSPLANT: OUTCOMES OF YOUNG ADULTS AND ADULTS IN A MEXICAN PUBLIC HOSPITAL
por: Sotomayor Duque, Guillermo, et al.
Publicado: (2023)

PB2022: ELTROMBOPAG IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia
por: Lengline, Etienne, et al.
Publicado: (2018)

PB2428: CLINICAL EFFICACY AND HEALTH-RELATED QUALITY OF LIFE IN SEVERE APLASTIC ANEMIA TREATED BY UMBILICAL CORD BLOOD TRANSPLANTATION: A CROSS-SECTIONAL SURVEY IN CHINA
por: LI, Ping, et al.
Publicado: (2023)

PB1947: ELTROMBOPAG COMBINED WITH IST AS A MULTICENTER STUDY OF THE FIRST LINE TREATMENT OF CHILDREN WITH SAA.
por: Yang, L., et al.
Publicado: (2022)

Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia
por: Goronkova, Olga, et al.
Publicado: (2022)

Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers
por: Wan, Ziqi, et al.
Publicado: (2023)

PB2252: A PATIENT WITH SEVERE APLASTIC ANEMIA UNDERWENT ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION. EVIDENCE-BASED NURSING CARE OF PATIENTS COMPLICATED WITH ORAL AND LABIAL TISSUE ULCERATION
por: Wang, LI, et al.
Publicado: (2023)

PB2431: OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA IN PEDIATRIC POPULATION - A SINGLE CENTER EXPERIENCE FROM PUBLIC HOSPITAL
por: Patil, Rajesh, et al.
Publicado: (2023)

PB2471: EFFECT OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MODIFIED FC PRETREATMENT REGIMEN ON SEX HORMONE LEVELS IN CHILDREN WITH SEVERE APLASTIC ANEMIA
por: MA, Liangming, et al.
Publicado: (2023)

PB2468: A RETROSPECTIVE STUDY OF ELTROMBOPAG IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: MA, Liangming, et al.
Publicado: (2023)

P820: PREDICTING RESPONSE TO RABBIT ATG-BASED INTENSIVE IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG IN CHINESE ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA
por: Li, R., et al.
Publicado: (2022)

PB2316: EFFICACY AND SAFETY OF ELTROMBOPAG IN PEDIATRIC PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA AND ITS EFFECT ON CELLULAR IMMUNE FUNCTION
por: 吴, ?.
Publicado: (2022)

The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
por: Işık, Ayşe, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_uu3faqtmcs4p528199h6b5plft